The Patent Finder

Terms ending in 2043

Codiak Biosciences, Inc.

Every in-force patent on Codiak Biosciences, Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,545,728Treatment of Cancer Metastasis by Targeting Exosome Proteins
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,758,896High-Throughput Chromatography Screening for Extracellular Vesicles
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,616,712Sting Agonist Comprising Exosomes for Treating Neuroimmunological Disorders
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,648,907Membrane Protein Scaffolds for Exosome Engineering
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,728,098Methods of Producing Extracellular Vesicles
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Codiak Biosciences, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited